Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study

[1]  Jian‐chun Zeng,et al.  Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology , 2019, Bone Research.

[2]  P. Sfikakis,et al.  Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift , 2019, RMD Open.

[3]  T. Mimori,et al.  Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study , 2019, Modern rheumatology.

[4]  J. Ishikawa,et al.  Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years’ treatment for Japanese rheumatoid arthritis patients , 2018, Modern rheumatology.

[5]  Xiangpei Li,et al.  Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study , 2018, Clinical Rheumatology.

[6]  T. Mimori,et al.  Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan , 2017, Modern rheumatology.

[7]  Luan Luan,et al.  Burden of rheumatoid arthritis from a societal perspective: A prevalence‐based study on cost of this illness for patients in China , 2017, International journal of rheumatic diseases.

[8]  X. Li,et al.  Iguratimod in combination with methotrexate in active rheumatoid arthritis , 2016, Zeitschrift für Rheumatologie.

[9]  A. Boonen,et al.  The challenging interplay between rheumatoid arthritis, ageing and comorbidities , 2016, BMC Musculoskeletal Disorders.

[10]  C. Kelly,et al.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review , 2015, Therapeutic advances in musculoskeletal disease.

[11]  Xin-wang Duan,et al.  Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial , 2015, Clinical Rheumatology.

[12]  K. Takagishi,et al.  Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis , 2015, Modern rheumatology.

[13]  T. Mimori,et al.  Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial , 2014, Modern rheumatology.

[14]  Guixiu Shi,et al.  Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis , 2013, Clinical & developmental immunology.

[15]  Qiang Xu,et al.  A Novel Disease-Modifying Antirheumatic Drug, Iguratimod, Ameliorates Murine Arthritis by Blocking IL-17 Signaling, Distinct from Methotrexate and Leflunomide , 2013, The Journal of Immunology.

[16]  T. Mimori,et al.  Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial , 2013, Modern rheumatology.

[17]  J. Kremer,et al.  Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of north america cohort of rheumatoid arthritis patients , 2012, Arthritis care & research.

[18]  C. Bao,et al.  T-614 alters the production of matrix metalloproteinases (MMP-1 andMMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro. , 2012, International immunopharmacology.

[19]  D. Symmons,et al.  Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register , 2012, The Journal of Rheumatology.

[20]  Georg Schett,et al.  The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.

[21]  S. Wassenberg,et al.  Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study , 2011, Rheumatology International.

[22]  C. Bao,et al.  Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. , 2009, Arthritis and rheumatism.

[23]  C. Bao,et al.  T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis , 2008, Arthritis research & therapy.

[24]  C. Bao,et al.  Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial. , 2008, Chinese medical journal.

[25]  G. Herrero-Beaumont,et al.  Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[26]  C. Allaart,et al.  A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[27]  H. Hashimoto,et al.  Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study , 2007, Modern rheumatology.

[28]  P. Hannonen,et al.  Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis , 2005, Annals of the rheumatic diseases.

[29]  K. Tanaka,et al.  Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. , 2003, Rheumatology.

[30]  M. A. van de Laar,et al.  Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[31]  M. Kondo,et al.  Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. , 2001, The Journal of rheumatology.

[32]  K. Tanaka,et al.  T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. , 1995, Japanese journal of pharmacology.

[33]  K. Tanaka,et al.  Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication: inhibitory effect on the production of interleukin-1 and interleukin-6. , 1992, Journal of pharmacobio-dynamics.

[34]  G. Burmester,et al.  Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. , 2008, Arthritis and rheumatism.

[35]  A. Silman,et al.  Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.